Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission: A National Multi-center, Double Blinded, Randomized, Placebo Controlled Study

Trial Profile

Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission: A National Multi-center, Double Blinded, Randomized, Placebo Controlled Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms STOP IT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Oct 2015 Planned number of patients changed from 139 to 136, as reported by European Clinical Trials Database.
    • 08 Jun 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2012-002702-51).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top